Testing effectiveness (Phase 2)Study completedNCT03548207
What this trial is testing
JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 126